IDeA Clinical and Translational Research Development (CTR-D) Award (P20-Clinical Trial Optional)
ID: 350040Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $2M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350040

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-257.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Development (CTR-D) Award (P20), aimed at enhancing clinical and translational research capabilities in IDeA-eligible states. This funding opportunity, numbered PAR-23-257, seeks to develop infrastructure and human resources to address health challenges in these regions, ultimately fostering collaboration and increasing competitiveness for extramural funding. Organizations can apply for grants up to $1.5 million annually for a maximum of five years, with a submission deadline of October 9, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-257.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-257-Full-Announcement.html
    PAR-23-257.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing a funding opportunity for the IDeA Clinical & Translational Research Development (CTR-D) Award (P20). This initiative aims to enhance clinical and translational research capabilities, workforce development, and infrastructure in IDeA-eligible states, which typically have limited research capacity. The funding opportunity, numbered PAR-23-257, is part of the Institutional Development Award (IDeA) program, established to build biomedical research capacity in historically underserved states. Organizations can apply for grants up to $1.5 million annually over a maximum project period of five years. Key components include a structured leadership team and various cores focusing on administration, professional development, community engagement, research design, and health research. To ensure successful applications, all proposals must align with the goal of building research capacity and should include a comprehensive plan addressing diverse community needs and engagement strategies. Funding is limited to one application per organization and only those located in eligible states can apply. The process emphasizes adherence to both general and program-specific instructions, along with the importance of developing diverse research teams to enhance scientific innovation.
    Similar Opportunities
    IDeA Clinical and Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the IDeA Clinical and Translational Research Network (CTR-N) Award, a federal grant aimed at enhancing clinical and translational research capacity in IDeA-eligible states and jurisdictions. This initiative seeks to develop infrastructure and human resources necessary for addressing health challenges, strengthen research competitiveness, and foster collaboration among participating organizations. The program emphasizes addressing health disparities and requires applicants to demonstrate collaborative capacity, submit an Overall Plan detailing healthcare concerns and research goals, and include a Plan for Enhancing Diverse Perspectives. The award ceiling is set at $1,300,000, with applications due by October 9, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-241.html.
    IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Institutional Development Award (IDeA) Networks of Biomedical Research Excellence (INBRE) program, aimed at enhancing the biomedical research capacity in IDeA-eligible states. This grant opportunity supports statewide networks of higher education and research institutions to foster faculty research, mentoring, and student involvement, with a focus on developing institutional infrastructure. The program allows for a maximum annual budget of $2.75 million over five years, requiring each application to include a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research. Interested applicants can find more information and submit proposals by the closing date of May 22, 2025, and should direct inquiries to grantsinfo@nih.gov.
    Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Clinical and Translational Science Award (CTSA) Program, aimed at enhancing clinical and translational research through collaborative partnerships. This initiative invites applications for hubs that will focus on improving the efficiency of clinical translation, addressing health disparities, and fostering innovative research methodologies, with a particular emphasis on community engagement and workforce development. Successful applicants, which may include higher education institutions and nonprofit organizations, are expected to outline strategic management and demonstrate strong leadership, with projects capped at seven years and a submission deadline of September 28, 2027. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the funding opportunity page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-272.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Centers of Biomedical Research Excellence (COBRE) Phase 1 (P20) grants, aimed at enhancing biomedical research capacity at eligible institutions. The initiative seeks to establish thematic, multi-disciplinary centers that strengthen research infrastructure and support the development of investigators capable of competing for independent NIH research grants. This program is particularly significant for institutions in states with historically low success rates for NIH funding, as it aims to foster health-related research and improve competitiveness. Interested applicants can submit one application for funding, with a budget of up to $1.5 million annually for a maximum project period of five years, and must adhere to specific guidelines. The application deadline is January 30, 2025, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)," aimed at supporting studies that address barriers to the adoption and sustainability of evidence-based health interventions, particularly in underserved communities. The initiative encourages research that promotes equitable access to effective practices and explores methods for discontinuing ineffective or harmful interventions, emphasizing the importance of contextual factors and multidisciplinary collaboration. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with a maximum funding amount of $275,000 and a project period of up to two years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by May 7, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity for the Re-Issue of PAR-21-293 - Clinical and Translational Science Award (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to reissue a Notice of Funding Opportunity (NOFO) for the Clinical and Translational Science Award (CTSA) Program, aimed at establishing hubs that will contribute to a national consortium focused on accelerating the delivery of treatments to patients through advancements in clinical and translational science. This initiative is designed to foster meaningful collaborations and responsive projects among eligible applicants, which include various organizations and institutions. The anticipated NOFO is expected to be published in Summer 2024, with applications due by January 2025, and the estimated award date is set for December 16, 2025. Interested parties should prepare for the upcoming application process as no cost-sharing or matching is required for this cooperative agreement funding opportunity.
    Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Limited Competition Renewal of the Centers of Biomedical Research Excellence (COBRE) (Phase 2), aimed at enhancing biomedical research capacity at IDeA-eligible institutions. This program focuses on strengthening research infrastructure and developing investigators to secure independent research funding, extending support for an additional five years for established COBRE Phase 1 centers. Eligible institutions must demonstrate past successes under Phase 1, including publications and grant funding, and applications should include a multi-component structure with an Administrative Core and 2-5 Research Projects led by Early Stage or New Investigators. The total funding amount available is up to $1.5 million, with applications due by May 28, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-063.html.